ClinicalTrials.gg
Active, not recruitingNCT04277637Updated Jun 22, 2026

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

A Phase 1 interventional study of Sonrotoclax and Zanubrutinib in Mature B-Cell Malignancies, sponsored by BeOne Medicines. Active, not recruiting at 43 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
437
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.

Read the detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

02

Conditions studied

  • Mature B-Cell Malignancies

Keywords

  • NHL
  • BCL2 Inhibitor
  • CLL
  • MCL
  • MZL
  • SLL
  • WM
  • Bcl-2i
  • BTKi
03

In context

Lead sponsor

BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Confirmed diagnosis of one of the following:

NHL Cohorts:

  1. MZL i. R/R extranodal, splenic, or nodal MZL defined as disease that after, or was refractory to, at least one prior therapy ii. Active disease requiring treatment
  2. FL i. R/R FL (Grade 1, 2 or 3a based on the WHO 2008 classification of tumors of hematopoietic and lymphoid tissue) and defined as disease that relapsed after, or was refractory to, at least 1 prior systemic therapy
  3. DLBCL i. R/R DLBCL (including all subtypes of DLBCL) defined as disease that relapsed after, or was refractory to, at least two prior systemic therapies and has either progressed following or is not a candidate for stem cell transplant (due to comorbidities or non-responsiveness to salvage chemotherapy)
  4. Transformed indolent B-cell NHL i. Any lymphoma otherwise eligible for Part 1 that has transformed into a more aggressive lymphoma. Patients with transformation from CLL or SLL (Richter's transformation) are not eligible for Part 1

    CLL/SLL Cohorts:

  5. CLL/SLL diagnosis that meets the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria i. Disease characterized as Treatment Naive (TN) or R/R disease defined as disease that relapsed after, or was refractory to, at least 1 prior therapy ii. Requiring treatment as defined by history

    MCL cohorts:

  6. WHO-defined MCL i. R/R MCL defined as disease that relapsed after, or was refractory to, at least 1 prior systemic therapy; ii. Requiring treatment in the opinion of the investigator

WM cohorts:

g. WHO-defined WM (clinical and definitive histologic diagnosis) i. R/R disease defined as disease that relapsed after, or was refractory to, at least 1 prior therapy; ii. Meeting at least 1 criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenström's Macroglobulinemia (Dimopoulos et al 2014)

  • by computed tomography (CT)/magnetic resonance imaging (MRI), defined as:

    1. CLL: at least 1 lymph node > 1.5 cm in longest diameter and measurable in 2 perpendicular dimensions or clonal lymphocytes measured by flow cytometry
    2. DLBCL, FL, MZL, MCL, or SLL: at least 1 lymph node > 1.5 cm in longest diameter OR 1 extranodal lesion > 1.0 cm in the longest diameter, measurable in at least 2 perpendicular dimensions. For MZL, isolated splenomegaly is considered measurable for this study
    3. WM: serum immunoglobulin (Ig) M level > 0.5 g/dL
  • (ECOG) performance status of 0 to 2
  • Adequate organ function
  • Adequate pancreatic function indicated by:

    1. Serum amylase ≤ 1.5 x (ULN)
    2. Serum lipase ≤ 1.5 x ULN

Key Exclusion Criteria:

  • Known current central nervous system involvement by lymphoma/leukemia
  • Known plasma cell neoplasm, prolymphocytic leukemia, history of or currently suspected Richter's syndrome
  • Prior therapy ≥ 2 months with or progression on a B-cell lymphoma-2 (Bcl-2) inhibitor

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
437 participants (actual)

Study arms

  • Experimental
    Sonrotoclax Monotherapy Dose Finding: Part 1

    Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL, mantle cell lymphoma (MCL); Waldenströms macroglobulinemia (WM); and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) will receive oral sonrotoclax evaluated as monotherapy.

    Drug: Sonrotoclax

  • Experimental
    Sonrotoclax Monotherapy Expansion Cohorts: Part 2

    Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral sonrotoclax at the RP2D dose to further define the safety profile.

    Drug: Sonrotoclax

  • Experimental
    Sonrotoclax + Zanubrutinib Combination Therapy Dose Finding: Part 3

    Participants with R/R MCL, R/R or treatment-naïve (TN) CLL/SLL will receive oral sonrotoclax in combination with zanubrutinib.

    Drug: Sonrotoclax · Drug: Zanubrutinib

  • Experimental
    Sonrotoclax + Zanubrutinib Combination Therapy Dose Expansion: Part 4

    Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral sonrotoclax in combination with zanubrutinib at an RP2D dose to further define the safety profile.

    Drug: Sonrotoclax · Drug: Zanubrutinib

  • Experimental
    Sonrotoclax + Zanubrutinib Combination Therapy Dose Escalation: Part 5

    Participants with treatment naïve CLL/SLL will receive oral sonrotoclax in combination with obinutuzumab without and with zanubrutinib.

    Drug: Sonrotoclax · Drug: Zanubrutinib · Drug: Obinutuzumab

  • Experimental
    Sonrotoclax + Zanubrutinib Combination Therapy Dose Expansion: Part 6

    Participants with treatment naïve CLL/SLL will receive oral sonrotoclax in combination with obinutuzumab without and with zanubrutinib at an RP2D dose to further define the safety profile.

    Drug: Sonrotoclax · Drug: Zanubrutinib · Drug: Obinutuzumab

Interventions

  • Film-coated tablets administered once daily at a dose as specified in the treatment arm

    Also known as: BGB-11417

  • 320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)

    Also known as: BGB-3111

  • Given as an intravenous infusion administered per label.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 30 days after the last dose of study drug, an average of 18 months

  2. Number of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: Up to 30 days after the last dose of study drug, an average of 18 months

  3. Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax

    Time frame: Up to 30 days after the last dose of study drug, an average of 18 months

  4. Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax

    Time frame: Up to approximately 2 months

  5. Part 1, Part 3, Part 5: RP2D of Sonrotoclax

    Time frame: Day 1 to last dose of study drug, an average of 18 months

  6. Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events

    Time frame: Up to 30 days after the last dose of study drug, an average of 18 months

  7. Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs

    Time frame: Up to approximately 2 months

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) After a Single Dose of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  2. Area Under the Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) After a Single Dose of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  3. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) After a Single Dose of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  4. Time Taken for Half the Initial Dose Administered to Be Eliminated from The Body (T1/2) of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  5. Time to Maximum Plasma Concentration (Tmax) After a Single Dose of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  6. Apparent Clearance (CL/F) After a Single Dose of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  7. Apparent volume of distribution (Vz/F) After a Single Dose of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  8. Steady State Area Under the Concentration-Time Curve of 0 - Last Day (AUCLast, ss) of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  9. Part 3, Part 4: Steady State Area Under the Concentration-Time Curve of 0 - Last Day (AUCLast, ss) of zanubrutinib

    Time frame: Predose up to 12 hours postdose

  10. Steady State Maximum Observed Plasma Concentration (Cmax, ss) of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  11. Part 3, Part 4: Steady State Maximum Observed Plasma Concentration (Cmax, ss) of zanubrutinib

    Time frame: Predose up to 12 hours postdose

  12. Steady State Trough Observed Plasma Concentration (Ctrough, ss) of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  13. Part 3, Part 4: Steady State Trough Observed Plasma Concentration (Ctrough, ss) of zanubrutinib

    Time frame: Predose up to 12 hours postdose

  14. Steady State Time to Maximum Plasma Concentration (Tmax, ss) of Sonrotoclax

    Time frame: Predose up to 12 hours postdose

  15. Part 3, Part 4: Steady State Time to Maximum Plasma Concentration (Tmax, ss) of zanubrutinib

    Time frame: Predose up to 12 hours postdose

  16. Part 2: AUC of Sonrotoclax administered after a high fat/calorie meal (HF-Fed)

    Time frame: Predose up to 12 hours postdose

  17. Part 2: Cmax of Sonrotoclax administered after a high fat/calorie meal (HF-Fed)

    Time frame: Predose up to 12 hours postdose

  18. Part 2, Part 4, Part 6: Overall Response Rate (ORR) as Assessed by the Investigator

    ORR is defined as the proportion of participants who had confirmed complete response Complete Response (CR) or Partial Response (PR)

    Time frame: Up to 18 months

  19. Part 2: Major Response Rate (MRR) for WM as Assessed by the Investigator

    Time frame: Up to 18 months

  20. Part 6: Minimum residual disease (MRD) negativity as measured by next generation sequencing

    Time frame: Up to 18 months

07

Study locations

43 sites
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2020 (actual). Primary completion is estimated for May 2027, 86 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2020
First posted
Feb 20, 2020
StartActual
Mar 24, 2020
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04277637
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Feb 20, 2020
Start date
Mar 24, 2020
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion